Safety & effectiveness study to evaluate if prophylactic left atrial appendage exclusion reduces occurrence of ischemic stroke or systemic embolism in cardiac surgery patients with elevated risk of stroke and no history of atrial fibrillation
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator Synergy Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia
We are Humbled by Our Talented Board and Employees!
Our responsibility to advance Diversity, Equity, and Inclusion is driven by a passionate belief that diverse thinking, skills, and experience bring the best outcome to our work as we innovate products and therapies that improve patients’ lives.
The EnCompass® Clamp is the newest innovation in bipolar RF ablation. EnCompass provides a magnetic guide, parallel closure, and uniform tissue pressure – while harnessing the technology we know works well.
The EnCompass® Clamp is the newest innovation in bipolar RF ablation. EnCompass provides a magnetic guide, parallel closure, and uniform tissue pressure – while harnessing the technology we know works well.
Do you have patients with inappropriate sinus tachycardia (IST)? If they’ve become refractory or intolerant to medications, they may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://bit.ly/clinical-heal-ist
Do you have patients with inappropriate sinus tachycardia (IST)? If they’ve become refractory or intolerant to medications, they may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://bit.ly/clinical-heal-ist
A metanalysis of CONVERGE and Real-World Data showed a 30-day major adverse event rate of 4% with a 95% confidence interval of 3-6% among more than 1,100 Hybrid Convergent Patients studied. See more #HybridAFTherapy data at https://bit.ly/47WQBk8
A metanalysis of CONVERGE and Real-World Data showed a 30-day major adverse event rate of 4% with a 95% confidence interval of 3-6% among more than 1,100 Hybrid Convergent Patients studied. See more #HybridAFTherapy data at https://bit.ly/47WQBk8
Vass Shantalov is now over a year and a half out from Hybrid AF™ Therapy! Free from Afib, all restrictions, and all medication, he has more energy to do the things he loves.
Vass shares he has gotten back to hiking, giving back, and traveling. And has even served on a mission trip.
Did you miss his full story? Watch now https://bit.ly/3saAUVQ
Vass Shantalov is now over a year and a half out from Hybrid AF™ Therapy! Free from Afib, all restrictions, and all medication, he has more energy to do the things he loves.
Vass shares he has gotten back to hiking, giving back, and traveling. And has even served on a mission trip.
Did you miss his full story? Watch now https://bit.ly/3saAUVQ
Do you have inappropriate sinus tachycardia (IST)? If you've become resistant or intolerant to your medications, you may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://bit.ly/clinical-heal-ist or join our Facebook page: https://bit.ly/3Pn9NAj
Do you have inappropriate sinus tachycardia (IST)? If you've become resistant or intolerant to your medications, you may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://bit.ly/clinical-heal-ist or join our Facebook page: https://bit.ly/3Pn9NAj
Meet our VP of Global and Professional Education, Lillian Palmer! Lily’s parents immigrated from Cuba, and many are surprised to learn English is her second language. Coming from a diverse background, Lily is passionate about mentoring young women and sharing tips for a successful career and life. #HispanicHeritageMonth
Meet our VP of Global and Professional Education, Lillian Palmer! Lily’s parents immigrated from Cuba, and many are surprised to learn English is her second language. Coming from a diverse background, Lily is passionate about mentoring young women and sharing tips for a successful career and life. #HispanicHeritageMonth
Your Afib symptoms are important, and so is receiving treatment. If left untreated, Afib can scar, stretch and stiffen the heart muscle which can cause palpitations, chest discomfort, fatigue and dizziness.
Talk to your doctor about your symptoms and your options.
To learn more, visit https://bit.ly/3QGQQpj
Your Afib symptoms are important, and so is receiving treatment. If left untreated, Afib can scar, stretch and stiffen the heart muscle which can cause palpitations, chest discomfort, fatigue and dizziness.
Talk to your doctor about your symptoms and your options.
To learn more, visit https://bit.ly/3QGQQpj
Vass Shantalov is now over a year and a half out from Hybrid AF™ Therapy! Free from Afib, all restrictions, and all medication, he has more energy to do the things he loves.
Vass shares he has gotten back to hiking, giving back, and traveling. And has even served on a mission trip.
Did you miss his full story? Watch now at https://bit.ly/3saAUVQ
Vass Shantalov is now over a year and a half out from Hybrid AF™ Therapy! Free from Afib, all restrictions, and all medication, he has more energy to do the things he loves.
Vass shares he has gotten back to hiking, giving back, and traveling. And has even served on a mission trip.
Did you miss his full story? Watch now at https://bit.ly/3saAUVQ
Are you located in Sydney or Melbourne and have 5 years of medical device marketing experience? Do you have experience with developing marketing plans, product launches, forecasting and demand planning, and KOL strategy? This new position in Australia may be your next career move. https://bit.ly/45KZCeg
Are you located in Sydney or Melbourne and have 5 years of medical device marketing experience? Do you have experience with developing marketing plans, product launches, forecasting and demand planning, and KOL strategy? This new position in Australia may be your next career move. https://bit.ly/45KZCeg
Do you have patients with inappropriate sinus tachycardia (IST)? If they’ve become refractory or intolerant to medications, they may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://lnkd.in/gZ4-GaWW
Do you have patients with inappropriate sinus tachycardia (IST)? If they’ve become refractory or intolerant to medications, they may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://lnkd.in/gZ4-GaWW
The information on this page is intended for Healthcare Professionals. If you are a Patient or a Caregiver, please visit the 'Patients and Caregivers' page.
Click "Agree" to confirm you are a Healthcare Professional.
The information on this page is intended for Healthcare Professionals. If you are a Patient or a Caregiver, please visit the 'Patients and Caregivers' page.
Click "Agree" to confirm you are a Healthcare Professional.
The information on this page is intended for Patients and Caregivers. If you are a Healthcare Professional, please visit the 'Healthcare Professionals' page.
Click "Agree" to confirm you are a Patient or a Caregiver.
You are leaving the AtriCure Asia Pacific site
You are leaving the Asia Pacific site of AtriCure.com and entering an AtriCure site intended for users in USA.
You are leaving the AtriCure Asia Pacific site
You are leaving the Asia Pacific site of AtriCure.com and entering an AtriCure site intended for users in Canada, Central & South America.
You are leaving the AtriCure Asia Pacific site
You are leaving the Asia Pacific site of AtriCure.com and entering an AtriCure site intended for users in Europe & Middle East.
You are leaving the AtriCure Europe & Middle East site
You are leaving the Europe & Middle East site of AtriCure.com and entering an AtriCure site intended for users in USA.
You are leaving the AtriCure Europe & Middle East site
You are leaving the Europe & Middle East site of AtriCure.com and entering an AtriCure site intended for users in Canada, Central & South America.
You are leaving the AtriCure Europe & Middle East site
You are leaving the Europe & Middle East site of AtriCure.com and entering an AtriCure site intended for users in Asia Pacific.
You are leaving the AtriCure Canada, Central & South America site
You are leaving the Canada, Central & South America site of AtriCure.com and entering an AtriCure site intended for users in USA.
You are leaving the AtriCure Canada, Central & South America site
You are leaving the Canada, Central & South America site of AtriCure.com and entering an AtriCure site intended for users in Asia Pacific.
You are leaving the AtriCure Canada, Central & South America site
You are leaving the Canada, Central & South America site of AtriCure.com and entering an AtriCure site intended for users in Europe & Middle East.
The EnCompass® Clamp is the newest innovation in bipolar RF ablation. EnCompass provides a magnetic guide, parallel closure, and uniform tissue pressure – while harnessing the technology we know works well.
The EnCompass® Clamp is the newest innovation in bipolar RF ablation. EnCompass provides a magnetic guide, parallel closure, and uniform tissue pressure – while harnessing the technology we know works well.
We're grateful for the skilled #SurgicalTechs who ensure safe and smooth operating rooms each day. Thank you for all you do! #SurgicalTechWeek
We're grateful for the skilled #SurgicalTechs who ensure safe and smooth operating rooms each day. Thank you for all you do! #SurgicalTechWeek
Do you have patients with inappropriate sinus tachycardia (IST)? If they’ve become refractory or intolerant to medications, they may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://bit.ly/clinical-heal-ist
Do you have patients with inappropriate sinus tachycardia (IST)? If they’ve become refractory or intolerant to medications, they may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://bit.ly/clinical-heal-ist
A metanalysis of CONVERGE and Real-World Data showed a 30-day major adverse event rate of 4% with a 95% confidence interval of 3-6% among more than 1,100 Hybrid Convergent Patients studied. See more #HybridAFTherapy data at https://bit.ly/47WQBk8
A metanalysis of CONVERGE and Real-World Data showed a 30-day major adverse event rate of 4% with a 95% confidence interval of 3-6% among more than 1,100 Hybrid Convergent Patients studied. See more #HybridAFTherapy data at https://bit.ly/47WQBk8
social media channels to keep updated on the latest at AtriCure.